Oncology
Permanent URI for this collection
Browse
Recent Submissions
Item Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.(Elsevier, 2024-04-30) Penault-Llorca, F; Dalenc, F; Chabaud, S; Cottu, P; Allouache, D; Cameron, D; Grenier, J; Venat Bouvet, L; Jegannathen, A; Campone, M; Debled, M; Hardy-Bessard, A-C; Giacchetti, S; Barthelemy, P; Kaluzinski, L; Mailliez, A; Mouret-Reynier, M-A; Legouffe, E; Cayre, A; Martinez, M; Delbaldo, C; Mollon-Grange, D; Macaskill, E J; Sephton, M; Stefani, L; Belgadi, B; Winter, M; Orfeuvre, H; Lacroix-Triki, M; Bonnefoi, H; Bliss, J; Canon, J-L; Lemonnier, J; Andre, F; Bachelot, T; Oncology; MedicalAndDental; Sephton, MatthewThe purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III UNIRAD trial, which evaluated the addition of everolimus to adjuvant endocrine therapy in high-risk, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.